Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.

Advertisement

Related Content

Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register